| Molecular Diagnostics of Lung Cancers at the Brigham and Women's Hospital and Dana-Farber Cancer Institute: Technology in Rapid Evolution. | |
| | |
MedLine Citation:
|
PMID: 23020723 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
The past 9 years have seen a remarkable shift in the diagnostic and therapeutic approach to lung carcinomas, beginning with the discovery of EGFR mutations and their role in directing management with targeted tyrosine kinase inhibitors. This special review recounts the experiences at one molecular diagnostic testing center, the Brigham and Women's Hospital/Dana-Farber Cancer Institute, from the initial research observations in 2003 to the development of multigene next-generation sequencing in 2012. Throughout this time, the activities in the molecular diagnostics laboratory have been in a state of rapid flux, responding to changes in clinical needs and scientific discoveries. |
| | |
Authors:
|
Neal Lindeman |
Related Documents
:
|
23323793 - Variants of uncertain significance in brca testing: evaluation of surgical decisions, r... 15103373 - Competition and mutualism among the gut helminths of a mammalian host. 15865023 - Teaching efforts to spread tme surgery in sweden. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Archives of pathology & laboratory medicine Volume: 136 ISSN: 1543-2165 ISO Abbreviation: Arch. Pathol. Lab. Med. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-01 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7607091 Medline TA: Arch Pathol Lab Med Country: United States |
Other Details:
|
Languages: eng Pagination: 1198-200 Citation Subset: AIM; IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dilemmas in lung cancer staging.
Next Document: Treatment of ALK-Positive Non-Small Cell Lung Cancer.